1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Speciality European Pharma Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Speciality European Pharma Limited (SEP) is a pharmaceutical company. Its major focus is on the products aimed at the urology or urogynaecology markets in Europe. The company’s product portfolio consists of Bulkamid for the treatment of stress urinary incontinence, Mitem/Mitocin for the treatment of a variety of cancers including bladder cancer, Regurin XL and Regurin BD for the treatment of overactive bladder, Aquamid for plastic surgeries and Uraplex to treat the symptoms of overactive bladder. It has offices in the UK, Germany, France, Italy and Nordic Region. The company also operates through a subsidiary called Contura in Denmark. SEP is headquartered in London, the UK.

Speciality European Pharma Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Speciality European Pharma Limited - Pharmaceuticals and Healthcare - Deals and Alliances Profile
Table of Contents


Table of Contents 2

List of Tables
3

List of Figures
4
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Speciality European Pharma Limited, Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 7
Speciality European Pharma Limited, Medical Devices Deals, 2009 to YTD 2015 8
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deal Details 10
Asset Purchase 10
Speciality European Pharma Acquires Mitem From curasan 10
Partnerships 11
Speciality European Pharma Enters Into Co-Marketing Agreement With Rottapharm 11
Speciality European Pharma Limited - Key Competitors 12
Key Employees 13
Locations And Subsidiaries 14
Head Office 14
Other Locations and Subsidiaries 14
Appendix 15
Methodology 15
About GlobalData 15
Contact Us 15
Disclaimer 15


List of Tables

Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Key Facts 1
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Speciality European Pharma Limited, Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
Speciality European Pharma Limited, Deals By Therapy Area, 2009 to YTD 2015 7
Speciality European Pharma Limited, Medical Devices Deals, 2009 to YTD 2015 8
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Speciality European Pharma Acquires Mitem From curasan 10
Speciality European Pharma Enters Into Co-Marketing Agreement With Rottapharm 11
Speciality European Pharma Limited, Key Competitors 12
Speciality European Pharma Limited, Key Employees 13
Speciality European Pharma Limited, Other Locations 14
Speciality European Pharma Limited, Subsidiaries 14


List of Figures

Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 1
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 1
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 6
Speciality European Pharma Limited, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 7
Speciality European Pharma Limited, Medical Devices Deals, 2009 to YTD 2015 8

Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Acyl CoA Desaturase ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.